While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

The study included people taking different types drugs in this category—semaglutide (Wegovy and Ozempic), and tirzepatide (Mounjaro and Zepbound). While tirzepatide targets two hormones—GLP-1 ...